Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.70940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Reio Ueta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Oxaliplatin, Colorectal Neoplasms, Citrobacter freundii, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Oxaliplatin, a third‐generation platinum‐based chemotherapeutic agent, is widely used in the treatment of colorectal cancer (CRC). However, some patients do not respond effectively to oxaliplatin, and intrinsic resistance to the drug poses a significant challenge. Recent studies have revealed an association between the gut microbiome and the progression of CRC. We hypothesized that Citrobacter freundii , a component of the gut microbiome, contributes to oxaliplatin resistance by regulating specific gene expression in CRC cells.
Methods
A bacterial culture filtrate from Citrobacter freundii was employed in the experiments. The CRC cell line RKO, following exposure to this filtrate, was analyzed using high‐throughput RNA sequencing. Candidate genes were identified through MTT assays, siRNA knockdown, and overexpression experiments. Apoptosis and reactive oxygen species (ROS) assays were performed to investigate the underlying mechanisms. Finally, a xenograft mouse model was used to evaluate oxaliplatin resistance in vivo.
Results
Exposure to bacterial culture filtrate from Citrobacter freundii induced oxaliplatin resistance in RKO cells with downregulation of the NINJ2 gene as a possible molecular mechanism. Reduced NINJ2 gene expression suppressed oxaliplatin‐induced apoptosis and ROS generation. A tendency toward reduced oxaliplatin efficacy was observed in vivo when NINJ2 gene expression was suppressed.
Conclusion
This study demonstrates that Citrobacter freundii promotes oxaliplatin resistance in CRC through downregulation of NINJ2 gene. NINJ2 gene may serve as a predictive biomarker and therapeutic target to overcome oxaliplatin resistance in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
ORCID-Profile: Reio Ueta, Ken Saijo, Chikashi Ishioka
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ueta, R., Imai, H., Saijo, K., Kawamura, Y., Kodera, S., & Ishioka, C. (2025). Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70940
Vancouver
Ueta R, Imai H, Saijo K, Kawamura Y, Kodera S, Ishioka C. Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70940
BibTeX
@article{Ueta2025,
author = {Ueta, Reio and Imai, Hiroo and Saijo, Ken and Kawamura, Yoshifumi and Kodera, Shuto and Ishioka, Chikashi},
title = {Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70940}
}
EUVIMED